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Abstract
The morphogenesis of retroviral particles is driven by Gag and GagPol proteins that provide the major structural component
and enzymatic activities required for particle assembly and maturation. In addition, a number of cellular proteins are found
in retrovirus particles; some of these are important for viral replication, but many lack a known functional role. One such
protein is clathrin, which is assumed to be passively incorporated into virions due to its abundance at the plasma
membrane. We found that clathrin is not only exceptionally abundant in highly purified HIV-1 particles but is recruited with
high specificity. In particular, the HIV-1 Pol protein was absolutely required for clathrin incorporation and point mutations in
reverse transcriptase or integrase domains of Pol could abolish incorporation. Clathrin was also specifically incorporated into
other retrovirus particles, including members of the lentivirus (simian immunodeficiency virus, SIVmac), gammaretrovirus
(murine leukemia virus, MLV) and betaretrovirus (Mason-Pfizer monkey virus, M-PMV) genera. However, unlike HIV-1, these
other retroviruses recruited clathrin primarily using peptide motifs in their respective Gag proteins that mimicked motifs
found in cellular clathrin adaptors. Perturbation of clathrin incorporation into these retroviruses, via mutagenesis of viral
proteins, siRNA based clathrin depletion or adaptor protein (AP180) induced clathrin sequestration, had a range of effects
on the accuracy of particle morphogenesis. These effects varied according to which retrovirus was examined, and included
Gag and/or Pol protein destabilization, inhibition of particle assembly and reduction in virion infectivity. For each retrovirus
examined, clathrin incorporation appeared to be important for optimal replication. These data indicate that a number of
retroviruses employ clathrin to facilitate the accurate morphogenesis of infectious particles. We propose a model in which
clathrin contributes to the spatial organization of Gag and Pol proteins, and thereby regulates proteolytic processing of
virion components during particle assembly.
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Introduction
To establish a productive infection in host cells, retroviruses
have evolved strategies that employ numerous host factors to
facilitate their replication. Recently, several groups have applied
genome-wide RNAi screens to identify hundreds of candidate host
factors that may facilitate human immunodeficiency virus-1 (HIV-
1) and murine leukemia virus (MLV) infection [1,2,3]. Other
strategies to identify host factors that facilitate virus replication
include the identification of proteins that bind to viral proteins [4]
and analysis of the proteomes that are incorporated into virions
[5,6,7]. Indeed, host proteins involved in HIV-1 budding, such as
Tsg101 [8] and ALIX [9] can be found in virions. Additionally,
proteins that modulate virion infectivity such as cyclophilin A
(CypA) [10], and Hsc70 [11] can also be demonstrated to be virion
components. However, while proteomic analyses of purified HIV-
1 or MLV particles have revealed dozens of virion-associated host
proteins, no biological significance has been attached to the virion
association of many of them. One such protein is clathrin, which
previous reports suggest is only passively incorporated into
particles [6].
Clathrin has been intensively studied in the context of cell
biology (reviewed in [12]). It is a cytosolic protein that functions in
vesicle genesis and transport and, specifically, mediates endocytosis
from the plasma membrane and cargo trafficking from the trans-
Golgi network (TGN). Clathrin is comprised of a trimer of
180 kDa heavy chains (HC) that are arranged with their N-
terminal adaptor binding domains at the extremities of each leg of
a triskelion, while clathrin light chains (LC) bind to heavy chains
close to their C-termini. Clathrin adaptors (such as the AP family)
govern the sorting of specific cargoes into clathrin-coated vesicles
and recruitment of clathrin to membranes (reviewed in [13]).
Many of these adaptors contain motifs such as LWXW[DE] (W
indicates a bulky hydrophobic residue), or in the case of AP180,
repeated motifs with the sequence DLL, which bind to the clathrin
N-terminal b–propeller domain, and facilitate the recruitment of
clathrin to the plasma membrane [14,15].
Here, we demonstrate that clathrin is abundantly and specifically
incorporated into a range of diverse retrovirus particles, including
HIV-1, SIVmac, MLV and M-PMV through interactions with Gag
or Pol proteins. Indeed, several retroviral Gag proteins were found to
encode peptide motifs that drive clathrin incorporation and mimic
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those found in cellular clathrin adaptor proteins. We also show that
mutations in the motifs that mediate clathrin recruitment have a
range of effects on the accuracy of particle morphogenesis, or on
virion infectiousness, depending on the particular retrovirus that was
examined. In several cases, we demonstrate that these effects can be
recapitulated by reducing the available levels of clathrin in cells.
Results
Clathrin is abundantly and specifically incorporated into
HIV-1 particles
Initially, to discover potential host factors involved in HIV-1
replication, we set out to identify cellular proteins that are incorporated
into HIV-1 particles, using a slightly different strategy compared to
previous studies. To minimize the ‘‘noise’’ in such experiments, such as
contaminating cell debris, or passively incorporated proteins, and
prevent degradation of incorporated cellular proteins by the viral
protease, plasmids expressing codon-optimized HIV-1 Gag alone, or
protease-inactive (D25A, PR-) GagPol proteins were transfected into
293T cells. This generated a very high yield of virus-like particles
(VLPs) without apparent cytotoxicity. Silver and Coomassie blue
staining of SDS-PAGE gels (Figure 1A), loaded with iodixinal gradient-
purified GagPol VLPs revealed that five cellular proteins were
abundantly incorporated into GagPol VLPs and were resistant to
digestion by externally applied subtilisin. Mass spectroscopic analysis of
the excised bands identified these proteins as CypA, Hsp70, Hsp90,
AIP1/ALIX and clathrin HC (Figure 1A), all of which have previously
been identified as components of HIV-1 particles [5,6,9,10,11].
Strikingly, and in contrast to the other proteins that were found in
HIV-1 GagPol VLPs, both silver staining and Western blot analysis
revealed that clathrin HC was undetectable in particles simultaneously
generated using the HIV-1 Gag protein alone (Figure 1A). Moreover,
visual inspection of silver or Coomassie stained gels suggested that
clathrin HC was packaged into GagPol VLPs at exceptionally high
level, i.e. the level of clathrin HC in virions approached that of GagPol
(Figure 1A, right panel). To verify this finding with authentic virion
particles, the T-cell lines CEMX174 and MT2 were infected with
VSV-G pseudotyped, Env-defectiveHIV-1 at amultiplicity of infection
of ,1, washed extensively and progeny virions were harvested 40 h
later (Figure 1B). Western blot analysis revealed that clathrin HC was
abundantly incorporated into these virions. Indeed, in experiments
where virions were simultaneously generated via infection of T-cell
lines or transfection of 293T cells and the amount of clathrin
incorporated into virions directly compared by quantitative fluores-
cence-based Western blotting (LI-COR), we found that the T-cell
derived virions incorporate as much or more clathrin than the 293T-
derived particles (Figure S1). Moreover, we determined that 6 to 8% of
the total clathrin HC in the HIV-1 infected T-cell cultures appeared to
be present in extracellular virions rather than cells (Figure S1).
Consistent with previous findings that clathrin LC binds to the C-
terminal portion of clathrin HC and forms a stable complex with it
[12], clathrin LC was also incorporated into HIV-1 virions. Indeed,
when green fluorescent HIV-1 VLPs were generated by coexpression
of HIV-1 GagGFP and GagPol in cells stably expressing fluorescently
tagged clathrin LC (DsRed-clathrin LC), about 40% of the VLPs
were labeled with sufficient DsRed-clathrin LC to be visualized by
deconvolution microscopy (Figure 1C, Table S1). In contrast, only a
few VLPs generated by coexpression of GagGFP and Gag were red-
fluorescent. In similar experiments, authentic virions were generated
by transfection with a proviral plasmid encoding YFP embedded in
the stalk region of the MA domain of Gag into cells stably expressing
DsRed-clathrin LC. In this case, 70–80% of YFP+ virions contained
sufficient DsRed-clathrin LC to be visualized as colocalizing red
fluorescent puncta (Figure 1D, Table S1).
HIV-1 Pol is responsible for clathrin incorporation into
virions
Given that clathrin incorporation into HIV-1 particles appeared
Pol-dependent, we next attempted to map the sequences responsible
for its incorporation, using particles generated by expressing protease-
defective GagPol proteins and detection of virion associated clathrin
using Western blot or microscopy assays. Precise deletion of the
reverse transcriptase (RT) or integrase (IN) domain in this context did
not markedly affect VLP release but, surprisingly, both manipulations
abolished clathrin incorporation (Figure 1C and Table S1). Similarly,
several Pol truncations or point mutations, constructed in the context
of protease-defective proviral plasmid, also inhibited or abolished
clathrin incorporation (Figure 1E and Table S1). Specifically,
mutations in reverse transcriptase (RT), including L234A, that inhibit
RT dimerization [16] prevented clathrin incorporation as did
deletion of the IN C-terminal domain (CTD) as well as two so-
called ‘class II’ IN mutations, N184L and F185K [17]. Western blot
analysis of virions indicated that, while the levels of GagPol protein in
cells and virions were not apparently affected by these mutations,
clathrin incorporation was inhibited (Figure 1E). We even found that
the presence of the non-nucleoside RT inhibitor efavirenz, which
stimulates RT dimerization [16], during the production of VLPs,
inhibited clathrin incorporation into virions (Table S1). In contrast,
no effect on clathrin incorporation was observed for the active site IN
point mutant E152K (Figure S2). Taken together, these findings
demonstrate that multiple Pol domains are strictly required for
clathrin incorporation into HIV-1 VLPs. This suggests that the
overall conformation of Pol is critical for clathrin packaging, and
effectively made it impractical to map small motifs in Pol that might
be responsible for clathrin recruitment.
The adaptor-binding beta propeller domain of clathrin is
packaged into HIV-1 particles
Clathrin adaptors GGA and AP-1, 2 and 3 are known to bind to
the N-terminal 7-bladed b–propeller domain of clathrin HC [13].
This clathrin domain, encoded by residues 1–494aa is known to
Author Summary
The assembly and maturation of infectious retroviruses is
driven by two viral proteins, Gag and Pol. Additionally, a
number of cellular proteins are found in retrovirus
particles, many of which lack a known functional role.
One such protein is clathrin, which normally mediates
several physiological processes in cells and was previously
thought to be only passively incorporated into virions. In
this study we show that clathrin is actively, specifically and
abundantly incorporated into retrovirus particles. In
several cases, retroviral proteins encode peptide motifs
that mimic those found in cellular adaptor proteins that
are responsible for clathrin recruitment. The range of
retroviruses into which clathrin is packaged includes
human and simian immunodeficiency viruses as well as
other murine and simian retroviruses. Manipulations that
prevented clathrin incorporation into virions also caused a
variety of defects in the genesis of infectious retroviruses,
including viral protein destabilization, inhibition of particle
assembly and release, and reduction in virion infectious-
ness. The precise nature of the defect varied according to
which particular retrovirus was examined. Overall these
studies suggest that clathrin is frequently employed by
retroviruses to facilitate the accurate assembly of infec-
tious virions.
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Figure 1. Clathrin is recruited into HIV-1 particles by Pol. (A) Particles from HIV-1 GagPol or Gag expressing, or mock transfected, cells were
pelleted through 20% sucrose, treated with subtilisin and separated on Optiprep gradients. Particulate material in gradient fractions was analyzed by
silver staining (upper three panels). An expanded view of lane 4 from the gradients containing Gag and GagPol particles is shown to the right, with
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fold autonomously when expressed in the absence of other clathrin
domains [18]. Co-expression of N-terminal 1–494aa or 1–363aa
fragments of clathrin along with HIV-1 GagPol resulted in specific
incorporation of these clathin fragments into wild-type VLPs, but
not into IN dCTD VLPs (Figure 1F), mimicking the property of
endogenous full-length clathrin. Thus, the N-terminal adaptor
binding domain of clathrin HC was sufficient to drive its
incorporation into HIV-1 GagPol VLPs.
Clathrin incorporation into SIVmac particles is driven
primarily by Gag, with a minor contribution from Pol
To determine whether clathrin incorporation into virions is a
general feature of primate lentiviruses, we next determined
whether it also occurred in SIVmac. In contrast to results
obtained with HIV-1 Gag, analysis of VLPs generated using only
SIVmac Gag showed that clathrin was abundantly incorporated
into VLPs in the absence of Pol (Figure 2A). Mapping experiments
in which chimeric SIVmac/HIV-1 Gag proteins (Figure 2B) were
used to generate VLPs revealed that Gag proteins encoding the
SIVmac p6 domain, specifically SIV(HIV MA) and HIV(SIV p6),
yielded VLPs containing clathrin (Figure 2B and 2C lane 4 and
lane 6). Conversely, the reciprocal chimeric Gag proteins,
HIV(SIV MA) and SIV(HIV p6), generated VLPs that did not
incorporate clathrin (Figure 2B and 2C lane 3 and lane 5). Thus,
the differential abilities of HIV-1 and SIVmac Gag VLPs to
incorporate clathrin were clearly governed by the p6 domain.
Inspection of the SIVmac p6 protein sequence revealed two
‘DLL’ motifs (positioned at p6 residues 21–23 and 51–53) that are
absent in HIV-1 p6 (Figure 2D). Because the clathrin adaptor
AP180 employs multiple copies of a DLL motif in its C-terminal
domain to directly bind to clathrin HC [15], we mutated either or
both DLL motifs in SIVmac p6 and tested the ability of the
mutant Gag proteins to drive clathrin incorporation into VLPs.
Western blot analysis indicated that mutations in both motifs
(D21A, D51A) or the second motif only (D51A or L52S) reduced
clathrin incorporation to almost undetectable levels, while
mutation in the first DLL motif alone had little effect (Figure 2E).
To determine the clathrin domain that mediates packaging into
SIVmac Gag VLPs, expression plasmids encoding the 1–494aa or 1–
363aa clathrin HC N-terminal domains were coexpressed with
SIVmac Gag. As shown in Figure 2F, SIVmac VLPs efficiently
incorporated the clathrin HC N-terminal 1–494aa fragment, but
unlike HIV-1, the 1–363aa fragment was poorly incorporated
(Figure 2F, bottom panel). The significance of the difference in clathrin
sequence requirements for incorporation into HIV-1 versus SIVmac
virions is unclear at present, but in both cases the N-terminal adaptor
binding domain appeared to be responsible for driving incorporation.
Next, we tested whether SIVmac Pol, like HIV-1 Pol, could also
drive clathrin incorporation. To facilitate clathrin detection, an HA
tagged clathrin N-terminal domain (1–494aa) was co-transfected with
plasmids expressing either wild-type SIVmac GagPol, or mutants in
which either (i) the DLL motifs in p6 were mutated (DLL- GagPol),
(ii) IN was mutated (N184L) in a way analogous to that which blocks
clathrin incorporation into HIV-1 GagPol VLPs, or (iii) both p6 and
IN were mutated. SIVmac DLL- GagPol exhibited greatly
diminished clathrin packaging into VLPs (Figure 2G). However,
some clathrin incorporation was observed in SIVmac DLL- GagPol
VLPs, and this incorporation was completely abolished by additional
mutation at IN residue N184 (Figure 2G). Thus, in SIVmac, both
Gag and Pol contribute to clathrin incorporation into virions, but
Gag appears to play the dominant role and drives significantly more
clathrin incorporation than Pol.
Clathrin incorporation into gammaretrovirus and
betaretrovirus particles
The finding that clathrin was specifically packaged into HIV-1 and
SIVmac VLPs prompted us to ask whether clathrin incorporation is a
general property of retroviruses. Inspection of a variety of retroviral
Gag protein sequences revealed that some, but not all, encoded
putative clathrin binding peptides, including DLL and LLTLD
motifs in their Gag proteins. In particular, a prototype gammare-
trovirus,MLV and a prototype betaretrovirus, M-PMVwere selected
for further investigation. Putative clathrin binding motifs, DLL and
DLISLD respectively, were found in their Gag proteins proximal to
their late domains (a DLL motif at 156–158aa in MLV Gag and a
DLISLD motif at 129–133aa of M-PMV Gag respectively,
Figure 3A). Each of these viruses was found to package either
endogenously expressed clathrin HC, or coexpressed N-terminal
adaptor-binding domain fragments of clathrin HC (1–494aa or 1–
363aa, Figure 3B,C,D,E) into virions. This incorporation was specific
because mutations in respective putative clathrin binding sites in Gag
(DLL to ALL in MLV or DLISLD to DAASLD in M-PMV)
dramatically reduced this incorporation. Notably, the yield of virion
particles was unaffected by mutations in these clathrin recruiting
motifs (Figure 3B,C,D,E). Mutations in other candidate clathrin HC
binding sites in Gag (533LLTLD537 at the C-terminus of MLV Gag
and 30DLL32 in the matrix domain of M-PMV, respectively) caused
no reduction in clathrin incorporation, indicating that these other
candidate motifs do not play a critical role in clathrin packaging
(unpublished observations).
Overall, these findings demonstrated that clathrin can be specifically
incorporated into virions from widely divergent retroviruses, and that
this incorporation is driven by the adaptor-binding domain at the N-
terminus of clathrin HC. Moreover, clathrin incorporation sometimes
occurs via the action of peptide motifs in viral structural proteins that
mimic those found in cellular clathrin adaptors.
Involvement of clathrin in the genesis of infectious
retrovirus particles
To probe the role of clathrin in retrovirus replication, we
adopted a variety of approaches, including the analysis of viral
mutants that were defective for clathrin incorporation, as well as
salient protein identifications by mass spectroscopy. The lower three panels show a Western blot analysis, using an anti-clathrin HC antibody. (B)
Western blot analysis of CEM and MT2 cells and corresponding VLPs generated following single cycle infection (40 hrs) with Env-deleted, VSV G-
pseudotyped HIV-1, using anti-HIV-1 CA (upper panels) and anti-clathrin HC antibodies (lower panels). Note that the virion loading represent 1/5 of
the total sample, while the cell lysate represents 1/100 of the total sample, and exposure times were the same for cell lysates and virions. (C) 293T
cells stably expressing DsRed-clathrin LC were transfected with plasmids expressing HIV-1 Gag, protease-defective GagPol (D25A), or IN-deleted
GagPol, spiked in a 1:4 ratio with a plasmid expressing Gag-GFP. Particles were recovered through 20% sucrose, filtered, placed on a poly-Lysine
coated coverslip and imaged. The fields shown are 5 mm square. (D) Similar to C, except that the 293T cells stably expressing DsRed-clathrin LC were
transfected with an HIV-1 (MA-YFP) proviral plasmid and images are 10 mm squares. (E) Requirements for clathrin HC packaging into HIV-1 particles.
293T cells were transfected with various protease-defective (D25A) HIV-1 proviral plasmids, that were otherwise either wild-type, or bore additional
mutations in RT (L234A), IN (N184L, F185K) or an IN dCTD deletion. Cells and virions were analyzed by Western blotting with anti-HIV-1 CA and
clathrin HC antibodies. (F) Incorporation of N-terminal b-propeller domain of clathrin HC (1–494aa or 1–363aa) into HIV-1 GagPol-derived VLPs.
Plasmids encoding HA-tagged clathrin HC N-terminal domain (1–494aa or 1–363aa) were co-transfected with wild-type or IN dCTD HIV-1 protease-
inactive GagPol expression plasmids. Cells and VLPs were analyzed by Western blotting with anti-HIV-1 CA and anti-HA antibodies.
doi:10.1371/journal.ppat.1002119.g001
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depletion of clathrin using siRNA based approaches. Attempts to
deplete clathrin using siRNA were complicated by the fact that it is
highly abundant, has a relatively long half-life (20 h–50 h) [19,20]
and is essential for various cellular functions and for cell viability.
Therefore, while we were able to reproducibly deplete about
70–80% of endogenous clathrin HC (Figure S3A), it proved nearly
impossible to completely deplete the intracellular clathrin to a
sufficient extent such that a clathrin-deficient viral phenotype
could be analyzed. Moreover, since clathrin plays a critical role in
a number of cellular pathways, including trafficking of proteins
through the secretory pathway, distinguishing the direct effects of
depletion from indirect effects is challenging. Therefore, in order
to investigate the role that clathrin plays in retrovirus life cycles, we
employed multiple approaches including characterizing viruses
with mutations that prevent clathrin incorporation, reducing
clathrin expression by siRNA depletion (Figure S3A), and
overexpressing the C-terminal domain of the clathrin adaptor
AP180 to induce clathrin sequestration (Figure S3B) [21,22].
Clathrin incorporation and effects on HIV-1 Pol proteins
Several mutations in HIV-1 Pol were found to block clathrin
incorporation, including mutations in RT at the dimer interface
Figure 2. Clathrin is recruited into SIVmac particles by Gag (p6) with a minor contribution from Pol. (A) Western blot analysis of VLPs
generated using HIV-1 and SIVmac Gag expression plasmids. Blots were probed with anti-HIV-1 CA (upper) or anti-clathrin HC (lower) antibodies. (B,
C) The p6 domain of SIVmac gag mediates clathrin incorporation. A panel of chimeras were constructed using HIV-1 Gag and SIVmac Gag proteins
and encoded an HA epitope at their C-termini (B). Cell lysates and VLPs, harvested after transfection of the constructs depicted in (B) were analyzed
by Western blotting (C) with anti-HA and anti-clathrin HC antibodies. (D) Alignment of HIV-1(NL4-3) and SIVmac239 p6 sequences. Identities are
boxed in black, and putative binding motifs are highlighted by underlining or red boxes. (E) DLL motifs in p6 recruit clathrin into SIVmac Gag VLPs.
293T cells were transfected with wild-type or the indicated mutant SIVmac Gag expression plasmids. Cells and VLPs lysates were probed with anti-
Gag and anti-clathrin HC antibodies. (F) Incorporation of the N-terminal adaptor binding domain of clathrin HC into SIVmac Gag VLPs. Plasmids
encoding an HA-tagged 1–494aa, or 1–363aa clathrin N-terminal domain or EGFP-HA were co-transfected with an SIVmac Gag expression plasmid.
Cells lysates and VLPs were probed with anti-CA and anti-HA antibodies. (G) Incorporation of clathrin HC into virions via SIVmac Gag and Pol. A
plasmid expressing an HA tagged N-terminal clathrin HC domain (1–494aa) was co-transfected with SIVmac GagPol expression plasmids encoding
wild-type, DLL mutant, integrase mutant (N184L) or both mutations, respectively. Virion lysates were probed with anti-CA and anti-HA antibodies.
doi:10.1371/journal.ppat.1002119.g002
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(L234A), as well as class II and CTD-truncating mutations in IN
(N184L and dCTD) (Figure 1E). Unfortunately, these mutations
are pleiotropic, and may therefore have multiple effects on viral
replication by perturbing the tertiary structure and function of the
Pol protein. Although these mutations did not have discernable
effects on Gag and GagPol precursor protein levels in cells or
VLPs when the viral protease was inactivated by mutation
(Figure 1E), these mutations induced aberrant proteolytic cleavage
of Pol proteins and reduced levels of GagPol precursor in cells and
virions when protease was active [23,24] (Figure 4A, Figure S4).
Specifically, when HIV-1 proviruses were expressed in 293T cells,
the WT and Pol-mutant viruses generated similar levels of Gag
protein and its processed derivatives, but the levels of GagPol
precursor, partly processed intermediates and mature IN proteins,
detected using an anti-IN antibody, were diminished in the
mutants that failed to package clathrin into virions (Figure 4A,
Figure S4). Similarly, in a series of constructs that were made to
express GagPol protein with an HA-epitope fused at C-terminus of
Pol, reduced GagPol levels were detected using an anti-HA
antibody when mutations that blocked clathrin were introduced,
and aberrant processed derivatives were detected (Figure 4B).
While the RT and IN mutations both blocked clathrin
incorporation and induced PR-dependent Pol depletion, it was
not clear whether or how these two effects were causally related to
each other, given the pleiotropic nature of these mutations.
However, these results did suggest the possibility that clathrin
recruitment by Pol might inhibit its viral protease-dependent
depletion. To investigate this possibility, we examined Pol
processing in cells where the clathrin HC N-terminal domain
(1–494aa) or the full-length clathrin HC was overexpressed.
Notably, for two Pol mutants, namely RT(L234A) and IN(F185K),
clathrin HC (1–494aa) or full length clathrin HC overexpresssion
led to an increase in the levels of GagPol derived proteins,
including mature IN (Figure 4B and 4C). Conversely clathrin
overexpression had no, or only a slight effect, on IN (N184L or
dCTD) mutants (Figure 4B and 4C). Importantly, the effects of
clathrin HC overexpression were specific to Pol; there was no
significant effect on Gag precursor or processed derivative levels.
To further explore the idea that clathrin recruitment might
stabilize Pol in the presence of an active viral protease, we fused
the clathrin recruiting domain from SIVmac Gag, namely p6
(mutated in such a way so as not bind to Tsg101 and ALIX), to the
C-terminus of HIV-1 GagPol (IN dCTD). This chimera expressed
higher levels of Pol protein expression than an equivalent construct
containing the SIVmac p6 domain in which the DLL motifs were
mutated (Figure 4D). Together, these results are consistent with
the notion that clathrin recruitment results in the stabilization of
Pol proteins in the presence of an active viral protease. In support
of this idea, Western blot analyses revealed that clathrin HC
depletion using siRNA reduced the levels of GagPol precursor, IN,
and partly processed intermediate Pol proteins in cells transfected
with a WT HIV-1 proviral construct (Figure 4E). Importantly, the
levels of Gag protein (which are translated from the same viral
mRNA species) were not reduced by this manipulation. Further-
Figure 3. Clathrin is incorporated into MLV and M-PMV virions. (A) Putative clathrin binding sites proximal to L-domain sequences in MLV
p12 and M-PMV pp24 Gag proteins. (B and C) MLV particles incorporate clathrin HC or a coexpressed N-terminal 1–494aa clathrin HC fragment via
D156L157L158 motif in the p12 domain. Wild-type or DLL/ALL mutant MLV GagPol expression plasmids were transfected alone (B) or with a plasmid
encoding HA tagged clathrin HC 1–494aa (C) in 293T cells. Pelleted virions (B) or cell lysates and virions (C) were subjected to Western blot analysis
with anti-MLV CA and anti-clathrin HC (B) or anti-HA antibodies (C). (D and E) M-PMV particles incorporate endogenous clathrin HC or a N-terminal 1–
363aa clathrin HC fragment via a D128LISLD133 motif in the pp24 domain. Wild-type or DLISLD/DAASLD mutant M-PMV proviral plasmids (pSARM-4)
were transfected alone (D) or with a plasmid encoding an HA tagged clathrin HC 1–363aa (E). Cell lysates and virions were subjected to Western blot
analysis with anti-M-PMV CA and anti-clathrin HC (D) or anti-HA (E) antibodies.
doi:10.1371/journal.ppat.1002119.g003
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Figure 4. Effect of Pol mutations and clathrin on HIV-1 Pol expression. (A) Apparent instability of Pol protein in the presence of the viral
protease caused by mutations that block clathrin recruitment. 293T cells were transfected with wild-type and mutant proviral HIV-1 plasmids. Two
days post transfection, cell lysates were analyzed by Western blotting using anti-CA (upper panel) and anti-IN (lower panel) antibodies. ‘‘ns’’ indicates
a nonspecific band. (B and C) Increase of Pol protein levels expressed by mutant HIV GagPol expression plasmid by overexpression of the adaptor
binding N-terminal clathrin HC domain (B) or full length clathrin HC (C) in trans. 293T cells were transfected WT or mutant HIV-1 GagPol expression
plasmids bearing an HA tag at the IN C-terminus, along with an empty vector or plasmids expressing clathrin HC 1–494aa (B) or full length clathrin HC
(C). Two days post transfection, cell lysates were probed with anti-CA, anti-HA and anti-clathrin HC antibodies. (D) Increase in Pol protein expression
by fusion of a clathrin recruiting motif to the C-terminus of GagPol (IN dCTD). 293T cells were transfected an HIV-1 GagPol IN dCTD expression
plasmid bearing an HA epitope tag, and Tsg101/ALIX binding-defective SIVmac p6 domain that did (left lane) or did not (right lane) have intact DLL
motifs, at the IN C-terminus. Two days post transfection, cell lysates were probed with anti-CA and anti-HA antibodies. (E) Clathin depletion decreases
HIV-1 Pol protein levels. 293T cells were cotransfected with an HIV-1 proviral plasmid and luciferase (siLuc) or clathrin HC (siClathrin HC) targeting
siRNAs. Cell lysates were probed with anti-CA (left panel) and anti-IN (right panel) antibodies. (F) Clathrin sequestration decreases HIV-1 Pol protein
levels. 293T cells were cotransfected with 200 ng of HIV-1 proviral plasmid and either empty vector or increasing amounts of an AP180C expression
plasmid. Cell lysates were probed with anti-CA and anti-IN antibodies.
doi:10.1371/journal.ppat.1002119.g004
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more, AP180C overexpression also reduced the levels of
intracellular GagPol, IN and intermediate proteins without
affecting Gag levels (Figure 4F), again suggesting that clathrin
specifically stabilizes Pol proteins in HIV-1 infected cells.
When introduced into GagPol expression vectors that were then
used to transfect 293T cells, the class II HIV-1 IN mutations that
blocked clathrin incorporation (N184L, F185K or dCTD) had
only minor effects on overall particle yield (Figure 5A). However,
as expected, viruses encoding these mutations exhibited extremely
low infectivity (Figure 5B). More importantly, depletion of clathrin
HC using siRNA did not affect overall particle yield from 293T
cells (Figure 5C), but caused significant decrease in infectiousness
(5 to 20-fold) of HIV-1 particles generated by cotransfection with
an HIV-1 proviral plasmid (Figure 5D). Alternatively, overexpres-
sion of AP180 C-terminal domain (AP180C), which binds clathrin
and induces its mislocalization [21–22], reduced the incorporation
of clathrin into HIV-1 particles (Figure S5) and also reduced the
infectiousness of HIV-1 particles generated from a proviral
plasmid by .100 fold (Figure 5E) without affecting physical
particle yield (Figure 5C). However, clathrin HC depletion using
siRNAs, or perturbation by AP180C overexpression, had
comparatively modest, but nevertheless significant, effects (,3-
fold) on the infectivity of VSV G-pseudotyped HIV-1 particles
(Figure 5F and 5G). Thus, while clathrin depletion and
sequestration clearly impacted Pol protein levels and, consequent-
ly, virion infectivity, there was a significant discrepancy in the
magnitude of the infectivity impairment induced by clathrin
perturbation when VSV-G pseudotyped HIV-1 particles were
examined as compared to those generated using the natural HIV-1
envelope. Given clathrin’s role in the secretory pathway, it was
possible that clathrin perturbation might have effects on the HIV-
1 envelope protein that impact virion infectivity, independent of its
effects on Pol. In fact, generation of HIV-1 particles in the
presence of AP180C resulted in virions that contained primarily
unprocessed gp160 envelope protein, and very little gp120 (Figure
S6). Therefore, it appears likely that clathrin affects the trafficking
of the HIV-1 Env protein, or cellular factors required for Env
maturation. While these results indicate caution in the interpre-
Figure 5. Effect of Pol mutations and clathrin on HIV-1 infectivity. (A) Particle production by 293T cells transfected with WT or IN mutant HIV-
1 GagPol expression plasmids. Cell lysates and virions were subjected to Western blot analysis with an anti-CA antibody. (B) Infectious virion
production from 293T cells transfected with plasmids expressing WT or mutant HIV-1 GagPol expression plasmids, a GFP-expressing HIV-1 vector and
VSV-G. Infectious virus yield was measured using TE671 cells as targets, and FACS analysis to enumerate infected cells. (C) Particle production by 293T
cells transfected with an HIV-1 proviral plasmid (left panels) or plasmids expressing WT HIV-1 GagPol, a GFP-expressing HIV-1 vector and VSV-G (right
panels). Cells were also transfected with luciferase (siLuc) or clathrin HC (siClath. HC) targeting siRNAs where indicated. Alternatively, cells were
cotransfected with an empty plasmid vector or a plasmid expressing AP180C, where indicated. Cell lysates and virions were subjected to Western blot
analysis with an anti-CA antibody. (D) Infectious HIV-1 virion production, as measured by TZM-bl indicator assay, after transfection of 293T cells with
an intact HIV-1 proviral plasmid (NL4-3) and luciferase or clathrin HC targeting siRNAs. Data are expressed as relative light units (RLU). (E) Infectious
HIV-1 virion production, as measured by TZM-bl indicator assay, after transfection of 293T cells with an intact HIV-1 proviral plasmid (NL 4-3) and
either empty vector or a plasmid expressing AP180C. Data are expressed as in (D). (F) Infectious virion production from 293T cells transfected with WT
HIV-1 GagPol expression plasmids, a GFP-expressing HIV-1 vector and VSV-G. Cells were also transfected with luciferase (siLuc) or clathrin HC
(siClathrin HC) targeting siRNAs where indicated. Infectious virus yield was measured using TE671 cells as targets, and FACS analysis to enumerate
infected cells. (G) Infectious HIV-1 virion production, as measured by TZM-bl indicator assay, after transfection of 293T cells with Env-defective proviral
plasmids, a VSV-G expression plasmid and either an empty vector or a plasmid expressing AP180C. Data are expressed as in (D).
doi:10.1371/journal.ppat.1002119.g005
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tation of the effects of clathrin perturbation on virion infectivity,
results with M-PMV (see below) suggest the clathrin perturbation
using siRNA or AP180C expression does not cause a non-specific
effect on the infectivity of retroviruses, and in particular the
function of the VSV-G envelope protein. Thus, the effect of
clathrin siRNA and AP180C on VSV-G pseudotyped HIV-1
infectivity (Figure 5F and 5G) should be independent of effects on
the envelope protein.
Clathrin incorporation and effects on SIVmac Gag
In SIVmac, MLV and M-PMV Gag proteins, we noticed that
motifs responsible for clathrin incorporation into virions were
situated proximal to motifs responsible for recruitment of factors
(ESCRT pathway-associated proteins or ubiquitin ligases) involved
in viral budding (Figure 2D and 3A). In the case of SIVmac, one of
the two DLL motifs is positioned overlapping the putative ALIX
binding site at the C-terminus of p6 (Figure 6A). Therefore, to
facilitate an examination of the role for clathrin in SIVmac
replication, we first identified residues that were critical for ALIX
recruitment, as well as residues that were critical for clathrin
recruitment that could be mutated without disrupting ALIX
recruitment. An SIVmac Gag expression plasmid was subjected to
scanning mutagenesis throughout residues 41–60 of p6 (Figure 6A),
with mutations selected so as not to alter the underlying p6-Pol
(p6*) protein sequence. Mutant SIVmac Gag proteins were
coexpressed with HA-tagged ALIX, and ALIX incorporation into
VLPs was assessed by Western blot analyses (Figure 6B).
Mutations P44L Y45S, L52S and D51A/L52S dramatically affected
ALIX incorporation into VLPs, while the mutations D21A, D51A,
L58P and F59S, did not (Figure 6B) These results are consistent
with a recent study that also mapped the ALIX binding site in
SIVmac p6 [25]. Thus, the SIVmac p6 domain was capable of
recruiting clathrin and ALIX into VLPs through overlapping
peptide sequences (D21LL D51LL for clathrin and P44Y45 L52 for
ALIX), but mutants were readily identified that separately
inhibited these activities. Therefore, in the ensuing studies, an
SIVmac Gag protein encoding the D21A and D51A mutations in
p6 was termed (DLL-) and used as a clathrin–recruitment
defective mutant while the P44L/Y45S mutant was termed (PY-)
(Figure 6A) and used as a ALIX-recruitment defective mutant.
To investigate the potential role of clathrin recruitment by Gag
in SIVmac replication, we first compared the infectivity of
particles generated by wild type and (DLL-) SIVmac proviral
plasmids in a single round infectivity assay. A modest reduction (2–
3 fold) in infectiousness was observed as a consequence of DLL
motif mutations, with no obvious effect on physical particle yield
(Figure 6C and 6D). Similar results were obtained when VSV-G
pseudotyped SIVmac particles were used (unpublished observa-
tions). However, in spreading replication assays conducted in
C8166 cells, this modest difference was apparently amplified, and
the SIVmac (DLL-) virus was highly attenuated compared to the
wild-type counterpart (Figure 6E).
Given the proximity of the DLL motifs to the L-domains in
SIVmac Gag (Figure 6A), we next tested the effects of mutations
predicted to abolish the recruitment of Tsg101 (PTAP-), clathrin
(DLL-) and ALIX (PY-), either alone or in combination, on
particle release. Initially this was done in the context of SIVmac
Gag, in the absence of the viral protease (Figure 6F). Consistent
with a previous report [26], mutation of the PTAP motif alone had
a surprisingly modest effect on SIVmac particle yield. Moreover,
mutation of the ALIX binding sites had no discernable impact on
particle yield, when introduced either alone or in combination
with the PTAP mutation (Figure 6F and 6G). Strikingly, while the
DLL- mutation had no effect on VLP yield when introduced
alone, the combination of this mutation with the PTAP- mutation
dramatically diminished VLP yield (Figure 6F). This finding held
true when the SIVmac Gag protein was expressed using a human
codon optimized construct (Figure 6G). Overexpression of ALIX
has previously been reported to rescue PTAP-mutant HIV-1
particle release [27,28] and we found that overexpression of ALIX
restored the defect in VLP release associated with the PTAP-
DLL- double mutant (Figure 6G). This activity required an intact
ALIX binding site, because ALIX overexpression failed to rescue
the budding defect in the PTAP-DLL-PY- triple mutant
(unpublished observations). This finding indicates that the
PTAP-DLL- double mutant is fully competent to assemble into
virions, but requires ALIX overexpression to complete budding.
Importantly we also found that overexpression of AP180C
recapitulated the effect of the DLL- mutation in SIVmac Gag, and
inhibited the release of VLPs assembled using PTAP- Gag
(Figure 6H). AP180C overexpression did not inhibit particle
release when wild-type Gag was used and this finding suggested
that clathrin facilitates the completion of assembly and/or budding
of SIVmac particles, particularly when budding is impaired or
retarded by inhibition of Tsg101 recruitment.
To further characterize the defects in VLP release imposed by
the PTAP and DLL- mutations, we analyzed 293T cells expressing
wild-type and mutant SIVmac Gag proteins via scanning
electronic microscopy. To eliminate variations from transfection
levels, Gag expression constructs were utilized which contained an
internal ribosomal entry site (IRES) linked to a GFP coding
sequence on the same mRNA as Gag, and cells expressing
equivalent amounts of GFP were chosen for analysis. Virions
assembled using Gag proteins bearing individual PTAP- or DLL-
mutations exhibited no gross morphological abnormalities, and
numerous apparently spherical particles were observed on the
plasma membrane of cells (Figure 6I and Figure S7). However,
PTAP- DLL- double mutant Gag proteins exhibited a clear
morphogenesis defect (Figure 6I and Figure S7). Specifically, cells
exhibited hemispherical protrusions from their surfaces, but
complete spherical particles were almost never observed. Crucial-
ly, this morphological defect could be induced using the PTAP-
single mutant SIVmac Gag protein (but not the wild type Gag
protein) upon overexpression of AP180C (Figure 6J and Figure
S8). Together, these data strongly suggest that clathrin plays a
facilitating role in the morphogenesis of SIVmac virions that is
modest when measured in the context of a single cycle of SIVmac
assembly, but is sufficient to strongly enhance replication, and
becomes particularly evident when budding is inhibited or slowed
by mutation of the PTAP L-domain.
When SIVmac Gag proteins were expressed in the context of an
active viral protease, either using GagProtease (Figure 7A) or full-length
GagPol (Figure 7B) expression plasmids, the DLL- single mutation had
little or no effect on levels of cell associated Gag protein (Figure 7A and
7B). However, when the DLL- mutation was present in combination
with the PTAP- mutation, the steady state cell-associated levels of the
Gag precursor and processed derivatives were significantly diminished
(Figure 7A and 7B). Remarkably, overexpression of ALIX rescued this
defect and restored the level of PTAP- DLL- mutant SIVmac Gag
proteins to those expressed by the wild type Gag-protease and GagPol
expression plasmid (Figure 7A and 7B). Notably, the ability of ALIX to
restore PTAP- DLL- mutant SIVmac Gag protein levels required an
ALIX binding site, as this effect was not observed when a PTAP- DLL-
PY- mutant SIVmac GagPol expression plasmid was used (Figure 7B).
The effect of the DLL- mutation on SIVmac Gag expression levels
was partially recapitulated by clathrin sequestration using AP180C.
Specifically, AP180C overexpression caused a reduction in the levels of
Gag protein expressed by a PTAP- PY- mutant, but not wild-type,
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Figure 6. Effects of mutations in the DLL motif in SIVmac p6 on replication and particle morphogenesis. (A) Sequence of SIV p6
highlighting motifs that were mutated to specifically block recruitment of Tsg101 (PTAP), ALIX (PY) or clathrin (DLL). (B) Mapping of the ALIX-binding
site on SIVmac p6. WT or mutant SIVmac Gag expression plasmids were co-transfected with a plasmid expressing HA-tagged ALIX. Cell lysates and
pelleted VLPs were subjected to Western blot analysis with anti-CA and anti-HA antibodies. (C and D) Effects of DLL- mutation on SIVmac particle
yield and infectiousness. WT and DLL-mutant SIVmac proviral plasmids were transfected into 293T cells. Cell lysates and pelleted VLPs were subjected
to Western blot analysis with anti-CA antibody (C) and infectious virion release was quantitated using the TZM-bl assay (D). (E) Effects of DLL-
mutation on SIVmac replication. C8166 cells were inoculated with equal amounts (as determined by infectious virus measurement) of WT and D21A/
D51A mutant SIVmac virus. Supernatant samples were collected at 2–3 day intervals thereafter and the amount of infectious SIVmac contained
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GagPol expression plasmid (Figure 7C). Taken together, these findings
lead to the conclusion that clathrin interaction with SIVmac Gag
facilitates virion morphogenesis, with consequent effects on Gag
protein stability in the presence of the viral protease, especially when
budding is impaired.
The effects of the DLL- mutation on SIVmac Gag protein levels
were specific to Gag, and did not affect Pol protein levels
(Figure 7B). Similarly, a mutation in SIVmac Pol (analogous to the
HIV-1 IN N184L) that blocked Pol dependent clathrin incorpo-
ration (Figure 2G) caused a reduction in the level of SIVmac Pol
protein to an almost undetectable level, while Gag levels were
unaffected (Figure 7B). In contrast to the effect of ALIX on
SIVmac Gag expression, this Pol expression defect could not be
rescued by overexpression of ALIX. Thus, the effects of mutations
that reduce protease-dependent Gag stability and clathrin
incorporation were independent of those that affected Pol stability
and clathrin incorporation.
Effects of clathrin recruitment on MLV infectivity and Gag
proteins
Like SIVmac, MLV has a DLL motif proximal to its L-domain
that is responsible for clathrin incorporation (Figure 3A). Transfection
Figure 7. Effects of Clathrin, Tsg101 and ALIX on the levels of SIVmac Gag and Pol proteins. (A) Effects of DLL motif, PTAP and PY
mutations and ALIX overexpression on the expression of SIVmac Gag protein in the presence of an active viral protease. 293T cells were transfected
with WT or the indicated mutant SIVmac GagProtease expression plasmids along with an empty vector or an ALIX expression plasmid. Cell lysates
were subjected to Western blot analysis with an anti-CA antibody. (B) Effects of DLL motif, PTAP, PY and IN mutations, and ALIX overexpression on
the expression of SIVmac Gag and Pol proteins. 293T cells were transfected with WT or the indicated mutant SIVmac GagPol-HA expression plasmids
along with an empty vector an ALIX expression plasmid. Cell lysates were subjected to Western blot analysis with an anti-CA (upper panel) or anti HA
(lower panel) antibodies. (C) Effects of PTAP mutation and AP180C overexpression on the expression of SIVmac Gag protein in the context of GagPol.
293T cells were transfected with WT or the indicated mutant SIVmac GagPol-HA expression plasmids along with an empty vector or 250, 500 or
1000 ng of AP180C expression plasmid. Cell lysates were subjected to Western blot analysis with an anti-CA antibody.
doi:10.1371/journal.ppat.1002119.g007
therein was measured using the TZM-bl assay. (F) Effects of combined PTAP, PY and DLL-motif mutation on SIVmac Gag VLP yield. 293T cells were
transfected with plasmids expressing WT or the indicated mutant SIVmac Gag proteins. Cell lysates and pelleted VLPs were subjected to Western blot
analysis with anti-CA antibodies. (G) Effects of ALIX overexpression on SIVmac VLP yield. 293T cells were transfected with an empty vector or an ALIX
expression plasmid along with plasmids expressing codon-optimized versions of the WT or the indicated mutant SIVmac Gag proteins. Cell lysates
and pelleted VLPs were subjected to Western blot analysis with anti-CA antibodies. (H) Effects of AP180C overexpression on SIVmac VLP yield. 293T
cells were transfected with an empty vector or increasing amounts (0, 0.5, 1, or 1.5 ug) of an AP180C expression plasmid along with plasmids
expressing PTAP mutant or WT SIVmac Gag proteins. Cell lysates and pelleted VLPs were subjected to Western blot analysis with anti-CA antibodies.
(I) Scanning EM images of 293T cells transfected with plasmids expressing codon optimized WT or the indicated mutant SIVmac Gag-IRES-eGFP
cassettes. Cells were selected for imaging based on similar levels of GFP fluorescence. Additional examples are shown in Figure S7. (J) Scanning EM
images of 293T cells transfected with plasmids expressing codon optimized SIVmac Gag-IRES-eGFP cassettes, in the presence of AP180C. Cells were
selected for imaging based on similar levels of GFP fluorescence. Additional examples are shown in Figure S8.
doi:10.1371/journal.ppat.1002119.g006
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of an MLV GagPol expression plasmid in which the DLL motif was
mutated to either ALL or DAA, along with plasmids encoding VSV-
G and aGFP expressingMLV vector resulted in no defect in the yield
of physical particles (Figure 8A), but mutant particles were.100-fold
less infectious than WT particles (Figure 8B). Similar results were
obtained using full-length MLV proviral plasmids (unpublished
observations). Similarly, siRNA mediated clathrin depletion did not
affect particle yield (Figure 8C). However, clathrin depletion resulted
in only a modest reduction of MLV infectivity (Figure 8D). This may
be attributable to incomplete clathrin knockdown (approximately
20% of normal clathrin levels remained in siRNA transfected cells,
Figure S3A). Consistent with this notion, coexpression of WT and
DLL- mutant MLV GagPol at various ratios revealed that particles
were nearly fully infectious, even when a small fraction of the Gag
proteins contained therein harbored an intact DLLmotif (Figure 8E).
Therefore, we hypothesize that the residual clathrin recruited by WT
virus assembled in siRNA treated cells may be nearly sufficient to
fulfill its functional role.
Western blot analysis showed that substitutions in the MLV
DLL motif had no effect on cell- or extracellular virion- associated
levels of viral precursor Gag (Pr65) or processed p30 CA proteins
when expressed in the context of MLV GagPol or proviral
plasmids (Figure 8A and unpublished observations). This held true
when the DLL mutation was introduced alone, or in combination
with mutations in PPPY and/or PSAP motifs (unpublished
observations). However, Western blot analysis with an anti-p12
monoclonal antibody revealed a dramatic decrease in the levels of
the mature p12 protein associated with virions (Figure 8F).
Conversely the partly processed MA-p12 intermediate was present
at equivalent abundance in wild type and mutant virions. This
finding excluded the possibility that the p12 antibody failed to
recognize the DAA mutant p12 sequence and instead suggested
the possibilities that either the MA-p12 junction was not efficiently
processed in the DAA mutant, or that the DAA mutation created a
p12 that was aberrantly cleaved and as a consequence could not be
recognized by the p12 antibody. To investigate these possibilities,
a small amount of wild-type or DLL-mutant MLV Gag-Pol
expression plasmid was co-transfected with increasing amounts of
wild-type or mutant Gag expression plasmids (in a Gag-Pol : Gag
ratio of 1:0.5 to 1:16, (Figure S9)). This analysis suggested that the
DAA mutant and WT Gag proteins could be processed in trans by
coexpressed GagPol bearing the WT p12 sequence, yielding
mature p12 protein in extracellular virions with comparable
efficiency. Conversely, the DAA mutant GagPol protein failed to
generate the fully processed p12 in virions, even when a WT Gag
protein was provided in trans (Figure S9). In a similar experiment,
we used a different MLV-related GagPol expression plasmid (from
XMRV) whose p12 sequence is poorly recognized by the anti
MLV p12 antibody (Figure S10). When XMRV GagPol was
coexpressed with WT or DLL mutant MLV Gag proteins, the WT
and DLL mutant MLV p12 proteins were detected at approxi-
mately equivalent levels in the resulting virions (Figure S10). Thus,
both the WT and mutant MLV MA-p12 junction can be
efficiently processed by MLV or XMRV protease in trans resulting
in the appearance of the mature p12 protein in virions. In other
words, it appeared that the DLL motif regulates the activity of the
MLV protease in cis, but not in trans, and the absence of the DLL
motif in cis to the protease caused aberrant Gag processing and
absence of p12 in virions.
While the absence of the p12 protein in DLL-mutant MLV
virions appeared symptomatic of the defect induced by the clathrin
binding site mutation, it was not clear whether this lesion was the
direct cause of the infectivity defect. To test this, we generated
MLV particles using a construct, similar to one previously
described [29], in which the MA-p12 cleavage site was mutated
(S1KK) so that it could not be cleaved, resulting in the absence of
the mature p12 protein in virions (Figure 8G). In this context, the
DLL- mutation retained its deleterious effect on MLV infectivity
(Figure 8H). Thus, these findings suggested the existence of a
generalized morphological defect that included, but was not
limited to, p12 deficiency in MLV particles consequent to
mutation of the clathrin binding site.
Electron microscopic analysis of WT and DLL mutant MLV
expressing cells did not reveal any gross morphological alterations
in assembling or assembled particles (Figure S11A). Therefore, to
test for more subtle morphogenesis defects, we examined whether
DLL- mutant particles retained the ability to saturate the TRIM5a
restriction factor. This assay should test for the presence of a
stable, morphologically accurate capsid lattice, which is expected
to be required for efficient binding to, and saturation of TRIM5a.
Thus, increasing amounts of N-tropic MLV particles generated
using WT or DLL- mutant GagPol expression plasmids (Figure
S11B) were applied to human TE671 cells, which express a
TRIM5a protein that can recognize and restrict N-tropic MLV
capsids [30,31]. Simultaneously, a fixed and equal amount of
GFP-expressing WT B-tropic or N-tropic indicator virus was
applied to monitor TRIM5a saturation (Figure 8I). Wild-type N-
tropic MLV particles efficiently saturated TRIM5a and thereby
facilitated N-tropic MLV infection. However, particles containing
a mutation in the DLL motif in p12 were approximately 10-fold
less active in this TRIM5a saturation assay (Figure 8I and S11B).
The finding that the mutant virions were less ‘visible’ to human
TRIM5a suggests that their cores were not properly formed, or
unstable and, therefore, that the clathrin-binding motif in p12 is
important for accurate MLV particle morphogenesis.
Effect of clathrin on the infectiousness of M-PMV virions
Like SIVmac and MLV, the betaretrovirus M-PMV harbours a
motif (DLISLD) proximal to its L-domains that is responsible for
recruiting clathrin into virions. Notably, however, the morpho-
genesis pathway for M-PMV is quite different to that of SIVmac
and MLV, in that complete immature capsids are assembled in the
cytoplasm and move thereafter to the plasma membrane for
envelopment.
Mutation of the clathrin-recruiting motif in M-PMV Gag
reduced the infectiousness of M-PMV virions by 5-fold, without
affecting the yield of physical particles (Figure 9A and 9B) or
causing gross morphological abnormalities that could be visualized
by electron microscopic examination (unpublished observations).
Notably, clathrin depletion using siRNA or perturbation by
overexpression of AP180C had a negative effect on M-PMV
infectivity of similar magnitude to that of the clathrin binding site
mutation (Figure 9B and 9C). Importantly, however, the effect of
depletion or sequestration of clathrin on M-PMV infectivity was
specific to the WT virus; these manipulations had no effect on the
infectivity of the mutant M-MPV that could not recruit clathrin
(Figure 9B and 9C), suggesting that the clathrin binding site
mutation and the clathrin perturbation affected the same process.
It was surprising that the clathrin knockdown had a greater effect
on M-MPV infectivity compared to MLV infectivity (compare
Figure 8D and 9B), while M-PMV was less affected by clathrin
binding site mutations than was MLV (compare Figure 8B and 9B).
However, experiments in which M-MPV virions were generated
using mixtures of WT and DLISLD mutant proviral plasmids
showed that reduction in infectivity was approximately proportional
to the fraction of the Gag protein that was mutant versus WT
(Figure 9D). Thus, M-MPV infectivity appeared more sensitive to
partial depletion of clathrin, or partial removal of clathrin binding
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Figure 8. Disruption of clathrin incorporation into MLV particles is associated with impaired infectivity. (A and B) Loss of infectivity of
DLL- mutant MLV particles. 293T cells were transfected with wild-type or DLL-mutant MLV GagPol expression plasmids, along with a VSV-G expression
plasmid and a GFP-expressing MLV vector. Cell lysates were subjected to Western blot analysis with an anti-MLV CA antibody (A). TE671 cells were
inoculatedwith the supernatant of these cultures and the number of infected cells enumerated by FACS analysis (B). (C andD) Effect of clathrin depletion on
MLV infectivity. 293T cells were transfected as in (A and B) except that cells were also transfected with luciferase (siLuc) or clathrin HC (siClathrin HC)
targeting siRNAs where indicated. Western blotting analysis (C) and infectious virionmeasurements (D) were carried out as in (A and B). (E) Small amounts of
coexpressed WT MLV GagPol suppress the infectivity defect exhibited by DLL-mutant MLV GagPol. Varying amounts (0, 5, 10, 20, 40, 60, 80, 90, 95, or
100 ng) of wild-type (WT) GagPol expression plasmid were co-transfected with varying amounts (100, 95, 90, 80, 60, 40, 20, 10, 5, or 0 ng) of a DLL-mutant
MLV GagPol expression plasmid along with a VSV-G and GFP-expressing MLV vector plasmid. Infectious virion yield was measured using TE671 cells and
plotted as a function of the fraction of the GagPol plasmid that was WT. Mean values 6standard deviations are shown. (F) Absence of intact p12 in DLL
mutant MLV VLPs. Cell lysates and virions generated in (A) were subjected toWestern blot analysis with an anti-p12 antibody. (G and H) Absence of mature
p12 in virions is symptomatic but not the sole underlying cause of reduced infectiousness of DLL-mutant MLV virions. 293T cells were transfected with wild-
type or the indicated mutant MLV GagPol expression plasmids, along with a VSV-G expression plasmid and a GFP-expressing MLV vector. Western blotting
analysis (G) and infectious virion measurements (H) were carried out as in (A and B). (I) DLL-mutant MLV VLPs exhibit reduced ability to saturate TRIM5a.
TE671 cells were inoculated with a fixed dose of GFP-expressing MLV vectors packaged using N-MLV and B-MLV GagPol proteins in the presence of
increasing amounts of wild-type or DLL- mutant N-MLV VLPs, or B-MLV VLPs. The percentage of infected (GFP-positive) cells is plotted as a function of VLP
dose.
doi:10.1371/journal.ppat.1002119.g008
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sites from virions, than did MLV. Nonetheless, optimal infectious-
ness and replication of both viruses was clearly dependent on
clathrin recruitment by their respective Gag proteins.
Discussion
In this study, we identified clathrin as a component in a variety
of retrovirus particles, including members of the lentivirus (HIV-1
and SIVmac), gammaretrovirus (MLV) and betaretrovirus (M-
PMV) genera. Specifically, the Gag proteins of SIVmac, MLV and
M-PMV recruit clathrin HC using DLL or DLISLD motifs, which
mimic those commonly found in classical clathrin adaptors.
Additionally, HIV-1 Pol and, to some extent, SIVmac Pol were
capable of recruiting clathrin into virions, although the motifs
responsible could not be mapped because clathrin incorporation
appeared to be dependent on the conformational integrity of
multiple domains of the HIV-1 Pol protein.
Phenotypic characterization of mutant viruses and a combina-
tion of other techniques to perturb clathrin in virus-producing cells
(siRNA-based clathrin HC knockdown or AP180C overexpression),
revealed that clathrin can have a range of apparently distinct effects
on virion morphogenesis, depending on the particular retrovirus
examined. These effects are summarized in Table S2. In the case of
HIV-1, mutations or drugs (efavirenz) that affect RT dimerization
as well as class II IN mutations are known or thought to affect
protease activation [17,23,24,32,33,34,35]. We found that at least
some of these mutations blocked clathrin incorporation, and also
found that clathrin overexpression could ameliorate deficits in the
levels of Pol protein harboring some of the aforementioned
mutations. Moreover, depletion or sequestration of clathrin could
reduce the levels of Pol proteins in cells. This suggests that clathrin
may be directly involved in regulating protease activity, or perhaps
in stabilizing or retaining the products of Pol proteolytic cleavage
during HIV-1 morphogenesis.
Similarly, mutations in the clathrin-recruiting motif in the p6
domain of SIVmac Gag, as well as sequestration of endogenous
clathrin, decreased the level of the viral Gag protein in the presence
of the viral protease. However, these effects were only truly evident
when the viral PTAP motif was also mutated. Again this finding is
Figure 9. Effects of clathrin on M-PMV Infectivity. (A) No effect of clathrin binding site mutation or clathrin depletion on M-PMV particle yield.
293T cells were transfected with wild-type or DLISLD mutant M-PMV proviral plasmids, along with a VSV-G expression plasmid. Cells were
simultaneously transfected with luciferase (siLuc) or clathrin HC (siClath. HC) targeting siRNAs where indicated Cell lysates were subjected to Western
blot analysis with an anti-M-PMV CA antibody. (B) The DLISLD mutation inhibits M-PMV infectivity and knockdown of clathrin by siRNA inhibits WT
but not DLISLD mutant M-PMV infectivity. 293T cells were transfected with wild-type (white bars) or DLISLD mutant (black bars) GFP-expressing M-
PMV proviral plasmids (pSARM-X-GFP) along with a VSV-G expression plasmid, as in (A) along with luciferase (siLuc) or clathrin HC (siClath. HC)
targeting siRNAs where indicated. The yield of infectious virions in the culture supernatant was measured by FACS after inoculation of TE671 cells. (C)
AP180C overexpression inhibits WT but not DLISLD mutant M-MPV infectivity. 293T cells were transfected as in (B) except that the siRNAs were
replaced with an empty plasmid vector or an AP180C expression plasmid. The yield of infectious virions in the culture supernatant was measured as
in (B). (D) Varying amounts (0, 10, 20, 40, 80, 120, 160, 180, 190, or 200 ng) of wild-type (WT) GFP-expressing M-PMV proviral plasmid was co-
transfected with varying amounts (200, 190, 180, 160, 120, 80, 40, 20, 10, or 0 ng) of a DLISLD mutant plasmid and a VSV G expression plasmid. The
yield of infectious virions was measured on TE671 cells and plotted as a function of the fraction of the proviral plasmid that was WT. Mean values
6standard deviations (SDs; bars) are shown.
doi:10.1371/journal.ppat.1002119.g009
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consistent with the notion that clathrin regulates proteolysis of the
viral protein, or stabilizes the products of proteolysis, and the
magnitude of the effect is exaggerated to easily detectable levels if
budding is blocked or retarded. Notably, the apparent protease-
dependent instability of the PTAP- DLL- mutant Gag protein could
be largely reversed by overexpression of ALIX, strongly suggesting
that the PTAP- DLL- mutant Gag protein is not generically
unstable or acutely sensitive to proteolysis simply as a direct
consequence of the introduced mutations. Rather, this observation
reinforces the notion that protease-dependent SIVmac Gag
depletion, consequent to a failure to recruit clathrin, is exaggerated
by retarding the rate of particle budding.
In the case of MLV, there was no apparent effect of the DLL-
mutation on Gag precursor stability, even when the proximal
PPXY L-domain motif was mutated. However, there was a very
clear effect on the products of Gag proteolysis, in that p12 was
absent from virions. Moreover, the DLL mutation had major
effects on the infectivity of MLV particles, as well as the accuracy
of their morphogenesis, or their stability, as evidenced by the
relative inefficiency with which MLV cores were apparently
recognized by the TRIM5a restriction factor. However the precise
nature of the biochemical lesion responsible for this infectivity
defect remains to be completely defined. The absence of p12 from
virions could contribute to the infectivity defect, as p12 has been
shown to be a component of MLV preintegration complexes [36].
However, mutations that prevent the cleavage of p12 from MA did
not abolish the effect of the DLL-mutation on MLV infectivity,
suggesting additional effects of clathrin on particle morphogenesis.
In addition to effects on viral protein proteolysis, clathrin
appears to affect the morphogenesis and release of SIVmac
particles in the absence of the viral protease. Again, observing this
effect required the PTAP-motif to be mutated, and the effect could
be suppressed by overexpression of ALIX. The ability of ALIX
overexpression to suppress the two effects of clathrin binding site
mutation on SIVmac, namely; (i) an assembly defect in the
absence of the viral protease and (ii) Gag instability in the presence
of the viral protease, suggests that they are different manifestations
of the same defect in clathrin recruitment. This apparent ability to
affect both protease-dependent and protease-independent process-
es influences the generalized models that can be invoked to explain
the role of clathrin in retrovirus morphogenesis (see below).
It is interesting that the D51L52L53 motif in SIVmac Gag
overlaps with the ALIX binding site, raising the possibility that
ALIX and clathrin might compete with each other. Moreover,
inspection of multiple viral strains of the SIVsm/SIVmac/HIV-2
lineage reveals that all p6 sequences contain 1, 2 or 3 copies of a
DLL motif. In those that contain a single DLL motif, it appears
that one copy has been displaced by a PTAP motif. These
observations are suggestive of interplay between clathrin and the
ESCRT machinery that merits future investigation.
A caveat to the aforementioned conclusions is that mutations,
particularly in HIV-1 or SIVmac Pol might have pleiotropic
effects, and it therefore was difficult to assign cause and effect in
situations where, for example, Pol mutations both blocked clathrin
incorporation and caused decreases in the levels of Pol proteins.
Nonetheless, depletion or sequestration of clathrin could, in several
cases, at least partly recapitulate the effects of mutations that
blocked clathrin recruitment. The pleiotropic effect of HIV-1 Pol
mutations likely arises from the fact that they cause premature
protease activation, and because protease has multiple substrates
in Gag and Pol, a variety of effects on the accuracy of particle
assembly and Pol protein incorporation, and therefore particle
infectiousness, are predictable consequences. It is possible that the
pleiotropic effect of these mutations is a consequence of their
effects on clathrin recruitment. Indeed, overexpression of clathrin,
or fusion of a clathrin binding site in cis could increase the levels of
HIV-1 Pol proteins that were apparently destabilized by Pol
mutations. However, it was not possible to restore the infectious-
ness of Pol-mutant particles using this approach.
One factor that must be considered in arriving at a proposal for
general model for a role of clathrin in retroviral replication was that
the magnitude of the effect on infectious virion yield clearly varied
according to which retrovirus was examined. Additionally, clathrin
was not found to be efficiently incorporated into all retroviruses that
we tested. For instance, equine infectious anemia virus (EIAV) and
human endogenous retrovirus K (HERV-K) did not efficiently
incorporate clathrin (unpublished observations). Moreover, the
apparent effect of clathrin on retrovirus replication usually varied
according to whether the experimental manipulation was clathrin
binding site mutation, clathrin depletion, or clathrin sequestration.
In some cases (e.g. SIVmac Gag), the effect of mutations in defined
motifs responsible for clathrin recruitment was relatively modest in a
single cycle of replication, while in others (e.g. MLV) the effect was
dramatic. In the case of HIV-1, SIVmac and MLV the effects of
mutations that abolish clathrin incorporation were much greater
than the effects of clathrin depletion or sequestration. While this
may be due to pleiotropic effects of the mutations that were
introduced, it is also true that clathrin depletion or sequestration
using the techniques employed herein was incomplete and, at least
in the case of MLV, a relatively small fraction of the viral Gag
protein is needed to be capable of recruiting clathrin in order for
virions to be nearly fully infectious. Conversely, in the case of M-
PMV, the magnitude of the effect of clathrin binding site mutation
on particle infectivity was nearly precisely recapitulated by clathrin
depletion or sequestration. Moreover, the impaired infectivity of the
clathrin recruitment-defective mutant was not further impaired
reduced by clathrin depletion or sequestration. Thus, we can be
quite confident in the case of M-PMV case that clathrin enhances
infectivity primarily through the action of the DLISLD motif in
Gag. Details of the mechanism by which clathrin enhances M-PMV
infection remain to be investigated and are difficult at present due to
the paucity of reagents for studying this virus, but M-PMV may
make the most tractable system for future investigations.
It is challenging, based on these data, to make definitive general
conclusions as to the role of clathrin in retrovirus replication,
because the ultimate outcome, in terms of defined lesions that
occurred as a consequence of blocking clathrin recruitment, differed
in each retrovirus studied herein (Table S2). Moreover, in some
retroviruses Pol was responsible for clathrin recruitment, while in
others Gag was responsible. Although conceptually unsatisfying, it
may simply be the case that clathrin plays a completely different role
in each retrovirus. However, for HIV-1, SIVmac and MLV, a
common theme was that clathrin appeared to influence proteolysis
of the viral polyproteins. This would likely have different, potentially
pleiotropic, consequences for different retroviruses, including
infectivity and morphogenesis defects as well as apparent viral
protein instability. We observed all of these outcomes in this study
and each could be reasonably hypothesized to be the consequence
of mis-regulation of viral polyprotein processing.
Models that could potentially explain the aforementioned
phenomena include the idea that clathrin contributes to the spatial
organization of Gag and Pol proteins during particle assembly. As a
homotrimeric Gag or Pol binding protein, clathrin could bind to
multiple Gag or GagPol molecules simultaneously. Indeed, the
affinity of clathrin for cellular clathrin adaptors, and likely,
therefore, assembling Gag or Pol proteins, is dependent on their
multimerization/polyvalency [12,13]. The association of clathrin
with assembling Gag and Pol proteins could influence proteolysis of
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the viral proteins by positively or negatively influencing protease
dimerization (which is required for protease activity), by influencing
substrate (Gag or Pol) mobility and/or accessibility to the protease,
or by helping to retain or remove the products of partial or complete
proteolysis from a nascent virion as particle assembly and proteolysis
proceeds. Such a model can also be reconciled with the findings that
the effects of clathrin appear quite variable, from overt effects on
particle morphogenesis and viral protein stability to more subtle
effects on virion infectiousness.
Materials and Methods
Plasmids and construction
The proviral HIV-1 plasmid used throughout was pNL4-3
(NIH AIDS Research and Reference Reagent Program, Catalog
No. 114). A protease defective variant, and other mutants thereof,
were constructed by generating PCR products harboring muta-
tions in PR or RT or IN, that were digested with SphI and EcoRI
before subcloning. The SIVmac proviral plasmid was previously
described [37] and based on SIVmac239. An MLV proviral
plasmid (pNCS) was a gift from Stephen Goff and the M-PMV
proviral plasmid pSARM-4 was a gift from Eric Hunter.
Overlap-extension PCR was used to generate HIV-1, SIVmac,
MLV, and MPMV mutants. For HIV-1 Gag, HIV-1 GagPol,
SIVmac Gag, SIVmac GagProtease (Gag-PR) and SIVmac
GagPol expression plasmids, wild-type or mutant encoding
sequences were amplified by PCR, using primers that incorporat-
ed 59EcoRI and 39 NotI sites and inserted into the HIV-1-based
expression plasmid pCRV1 [38]. In some cases an HA epitope was
inserted, fused in frame at the C-terminus of the expressed protein
into pCRV1 vector. The panel of SIVmac double mutants PTAP-
(PTAP/LTAL) DLL-(DLL/ALL), PTAP- (PTAP/LTAL) PY-
(PY/LS) and DLL-(DLL/ALL) IN-N184L and triple mutants
PTAP- (PTAP/LTAL) PY-(PY/LS) DLL- (DLL/ALL) were
constructed by introducing additional point-mutation into pre-
constructed single or double mutants, respectively. To generate
chimeric HIV-1/SIVmac Gag proteins (Figure 2B), overlap-
extension PCR was performed with primers targeting the
corresponding region of SIVmac or HIV-1 Gag and PCR
products were inserted along with a C-terminal HA-epitope tag
into pCRV1. To insert mutant SIVmac p6 at the C-terminus of
mutant HIV-1 GagPol, NotI sites were incorporated at both 59
and 39 end of the SIVmac p6-encoding PCR product which was
inserted between HIV-1 Gag-Pol and the HA epitope in pCRV1.
Plasmids expressing codon-optimized SIVmac Gag, pCR3.1/
SIVmac-Gag, as well as codon-optimized HIV-1 Gag, codon-
optimized HIV-1 Gag-Pol and codon optimized GagGFP, were
previously described [38] and mutations were made by overlap-
extension PCR. To construct pCR3.1/SIVmacGag-IRES-eGFP
expressing both SIVmac Gag and GFP, the IRES-eGFP region was
amplified, using pIRES2-EGFP(Clontech) as template, digested by
NotI and subcloned at the C-terminus of SIVmac Gag in WT and
mutant pCR3.1/SIVmac-Gag expression plasmids.
For MLV mutants, PCR products harboring D156LL- mutations
(DLL/ALL or DLL/DAA) were digested using BsrGI and XhoI
and inserted into pCAGGS-basedMLVGag or Gag-Pol expression
vectors [39] or an N-tropic MLV GagPol expression plasmid [30].
For M-PMV mutants, PCR products bearing the DL129I130SLD/
DAASLD mutation were digested by SmaI/SacI and inserted into
pSARM-4 [40] or pSARM-X-eGFP as described in [41].
Plasmids expressing clathrin HC residues 1–363aa or 1–494aa
with a C-terminal HA or Myc epitope were amplified by using full-
length clathrin HC as a template and inserted into pCR3.1
(Invitrogen).
The plasmid expressing pCR3.1/ALIX, the HIV-1 proviral
plasmid bearing YFP in the stalk region of matrix (pNL4-3 MA-
YFP) and the XMRV (xenotropic murine leukemia-related virus)
GagPol expression plasmid were described previously [42,43,44].
The plasmid expressing FLAG-AP180C was a gift from Lois
Greene, a plasmid expressing DsRed-clathrin LC was a gift from
Sanford Simon and pSIV-T1 was from Francois-Loic Cosset [45].
Antibodies
Monoclonal antibodies included anti-HA (Covance), anti-
Clathrin HC (BD Transduction laboratories), anti-FLAG (Sigma),
anti-HIV capsid p24 (183-H12-5C), anti-Env (1D6), anti-RT
(MAb21) (all from NIH AIDS Research and Reference Reagent
Program), anti-HIV IN (a gift from Michael Malim), anti-MLV
capsid p30 (ATCC CRL-1912 R187), anti-MLV p12 (ATCC,
CRL-1890 548), and anti-M-PMV Gag (a gift from Eric Hunter)
[46]. In addition, secondary antibodies included goat anti-mouse
or anti rabbit IgG conjugated to horseradish peroxidase, or to
Alexa Fluor 488 (Invitrogen), IRDyeH 800CW and IRDyeH 680
(LI-COR Biosciences).
Cell lines and transfection
Adherent cell lines from human (293T, TE671, TZM-bl) were
maintained in DMEM supplemented with 10% fetal calf serum
and gentamycin. CD4+lymphoid cell lines CEMx174, MT2, MT4
and C8166 were grown in RPMI/10%FCS/antibiotics.
In general, for transfection experiments in 293T cells, cells were
seeded at a concentration of 1.56105 cells/well (24-well) or 36105
cells/well (12-well) or 26106(10-cm dish) and transfected the
following day using polyethylenimine (PolySciences).
To identify proteins incorporated into HIV-1 VLPs, 10 mg of
an HIV-1 GagPol and Gag expression plasmids were transfected
into 293T cells in 10 cm dishes. Particles in 30 ml of filtered
supernatant were pelleted through 20% sucrose, resuspended in
PBS, treated with subtilisin (Sigma) and separated on Optiprep
gradients. Particulate material in each of 8 fractions was recovered
by diluting the fractions with PBS and ultracentrifugation and
analyzed by SDS-PAGE followed by Coomassie blue or silver
staining. Bands of interest were excised and protein identification
was done by the Rockefeller University Proteomics Center. To
determine domains responsible for clathrin incorporation, 293T
cells were transfected with 5 mg of HIV-1 or SIVmac GagPol or
Gag expression plasmid along with 3 mg of clathrin heavy chain
1–494aa or clathrin heavy chain 1–363aa or 0.5 mg GFP-HA
expression plasmid. Analysis of clathrin incorporation into other
viruses was performed by transfection of 8 mg of MLV GagPol
expression plasmid or 8 mg of M-PMV proviral plasmid, with
or without 2 mg of clathrin HC 1–494aa or 2 mg of clathrin HC
1–363aa expression plasmids followed by ultracentrifugation and
subtilisin treatment of pelleted virions.
To measure SIVmac VLP release, cells were transfected with
150 ng of native sequence or codon-optimized SIVmac Gag
expression plasmids, along with 300 ng of ALIX expression
plasmid where indicated. In Figure 6H, 500 ng of codon
optimized SIVmac Gag was cotransfected with 0 ng, 0.5 mg,
1.0 mg or 1.5 mg of AP180C expression vector. VLPs were
harvested at 24 hrs post transfection, pelleted through 20%
sucrose and subjected to Western blot analysis.
To define the ALIX binding motif on SIVmac Gag, 500 ng of
plasmids expressing wild-type or mutant SIVmac Gag proteins
were cotransfected with 500 ng of pCR3.1/HA-ALIX into 293T
cells. Cell lysates and VLPs were harvested and analyzed by
Western blotting after 40 hrs.
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To generate infectious viruses bearing a GFP reporter, 293T
cells were transfected with 200 ng of an HIV-1 GagPol expression
plasmid and 200 ng of reporter vector pHRSIN-CSGW [47] (for
HIV-1), 200 ng of an SIVmac GagPol expression plasmid and
200 ng of reporter vector pSIV-T1 (for SIVmac), 200 ng of an
MLV GagPol expression plasmid and 200 ng of reporter vector
pCNCG [30] (for MLV), or 400 ng of pSARM-X-eGFP (for M-
PMV), along with 100 ng of plasmid expressing the VSV-G
envelope. To measure the effect of AP180C on infectiousness of
viruses, 500 ng of empty vector or AP180C expression plasmid
was added to the transfection mixture. To generate the VSV-G
pseudotyped noninfectious VLPs used in the TRIM5 saturation
assays in Figure 8I and Figure S11B, 10 mg of WT or DLL-
mutant N-tropic MLV and 2 mg of VSV-G expression plasmid
were used to transfect a 10 cm dish of 293T cells.
To determine the effects of AP180C on HIV-1 or SIVmac viral
protein expression level, 200 ng of HIV-1 proviral plasmid was
cotransfected with 0 ng, 300 ng, 600 ng, 900 ng of AP180C
expression plasmid (Figure 4F), or 200 ng of SIVmac GagPol
expression plasmid was cotransfected with 0 ng, 250 ng, 500 ng or
1000 ng of AP180C expression plasmid (Figure 7C).
To assess the ability of the MLV protease to process WT or
mutant Gag proteins (Figure S9), 50 ng of WT or DLL/DAA
mutant MLV GagPol expression plasmid were contransfected with
increasing amounts (0, 25 ng, 50 ng, 100 ng, 200 ng, 400 ng,
800 ng) of plasmid expressing WT or DLL/DAA mutant MLV
Gag. Alternatively, in Figure S10, 6 mg of XMRV GagPol
expression plasmid were cotransfected with 300 ng of WT or
DLL/DAA MLV Gag expression plasmid. Cell lysates and VLPs
were analyzed by Western blotting 48 hrs later.
In all transfection experiments, the total amount of DNA was
held constant within the experiment by supplementing transfection
mixtures where necessary with empty expression vector.
Infectivity assays
Transfected 293T cells were placed in fresh medium at 20
hrs post infection and virion containing cell supernatants were
harvested and filtered (0.22 mm) at 40 hrs post transfection.
Infectious virus release (for HIV-1 and SIVmac proviral plasmid
derived virus) was determined by inoculating TZM cells seeded
in 96 well plates at 1.26104 cells/well. At 48 hrs post infection,
b-galactosidase activity was determined using GalactoStar reagent
as per the manufacturer’s instructions.
Reporter viruses (HIV-1, SIVmac, Moloney MLV and M-
PMV) bearing a GFP indicator gene were generated by transient
transfection of 293T cells along with VSV G envelope protein, in
the absence or presence of AP180C as indicated above. TE671
cells were seeded one day prior to infection, inoculated with GFP
reporter viruses and FACS analysis was carried out using Guava
EasyCyte instrument (Guava Technologies).
TRIM5a saturation assays
TE671 were seeded at 26104 cells/well in 24-well plates one
day before infection. Cells were inoculated with a fixed dose of N-
MLV or B-MLV GFP reporter virus, selected so that infection
with the restricted virus in the absence of VLPs gave low, but
measurable, levels of infection (about 0.1% GFP-positive cells).
Restriction-abrogating VLPs were serially diluted two-fold and
added to the target cells simultaneously with the fixed dose of N-
MLV in the presence of polybrene. Infection by the GFP reporter
virus was measured 48 h later as described above.
RNAi
293T cells were transfected with 60–100 pmol of a clathrin-
specific RNA duplex (SMART pool, Dharmacon) or a control
firefly luciferase duplex (Dharmacon) using Lipofectamine2000
(Invitrogen) according to manufacturer’s instructions. Twenty-four
hours post-transfection cells were harvested and replated. Forty-
eight hours after the first transfection, cells were co-transfected with
siRNA (as above) and 200 ng of proviral plasmid or, in the case of
GFP-reporter viruses, 200 ng of GagPol expression plasmid, 200 ng
of corresponding retroviral reporter plasmid along with 100 ng of
VSV-G expression plasmid using Lipofectamine2000 (Invitrogen).
Virions and cells were harvested 48 hours later.
Western blot analysis
Cell lysates and pelleted virions or VLPs (recovered by
centrifugation through 20% sucrose) were separated on NuPage
Novex 4–12% Bis-Tris Mini Gels (Invitrogen). Proteins were
blotted onto nitrocellulose membranes. Thereafter, the blots were
probed with primary antibodies and a corresponding peroxidase
conjugated secondary antibody and were developed with WestPico
chemiluminescent detection reagents (Pierce). Alternatively, blots
were probed with antibodies as above, followed by secondary
antibodies conjugated to IRDye 800CW or IRDye 680.
Fluorescent signals were detected and quantitated using Odyssey
(LI-COR Biosciences).
Microscopy
293T cells stably expressing DsRed-Clathrin light chain were
seeded on 3.5-cm, glass-bottomed dishes coated with poly-L-
Lysine (Mattek). The following day, they were transfected with a
plasmid expressing AP180C, using Lipofectamine 2000. Cells were
fixed 24 hrs later and observed by deconvolution microscopy using
an Olympus IX70-based Deltavision microscopy suite as described
previously [48].
To generate fluorescent VLPs for microscopic analysis, 293T
cells stably expressing DsRed-clathrin LC were cotransfected with
plasmids expressing codon-optimized HIV-1 Gag, or Gag-Pol
along with a plasmid expressing codon optimized Gag-GFP at a
ratio of 4:1 or 8:1. Forty-eight hours post transfection the culture
supernatants were pelleted through a 20% sucrose cushion. The
resulting VLPs were resuspended in PBS, 0.22 mm filtered, and
diluted 1:1 with PBS containing 3% paraformaldehyde. They were
fixed overnight onto poly-L-Lysine coated glass bottom dishes and,
after permeabilization with 1% Trition X-100 and 0.5% SDS, the
VLPs were stained with anti-HIV capsid antibody, and analyzed
via microscopy (Deltavision, Applied Precision). Alternatively,
proviral plasmids pNL4-3 and pNL4-3 MA-YFP were transfected
in a 1:1 ratio into 293T expressing DsRed-clathrin LC, subjected
to the above protocol but were visualized without immunostaining.
For scanning electronic microscopy studies, 293T cells were
transfected with plasmids expressing codon optimized pCR3.1/
SIVmac Gag-IRES-eGFP cassette and inspected by fluorescent and
scanning electron microscopy using a Hitachi S4700 field emission
SEM (University of Missouri Electron Microscopy Core Facility).
For transmission electron microscopy, samples were fixed using
paraformaldehyde and glutaraldehyde, postfixed using osmium
tetroxide and then dehydrated and embedded in Embed-812
(EMS). Following polymerization, approximately 65 nm sections
were cut with an ultramicrotome and mounted on copper grids.
Sections were stained with uranyl acetate followed by lead citrate
and imaged using a FEI TECNAI G2 transmission electron
microscope.
Supporting Information
Figure S1 Quantitation of clathrin incorporation into virions
from infected CEMx174 or MT4 cells and transfected 293T cells.
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T-cell lines were infected with HIV-1(NL4-3) at an MOI of ,0.5,
washed extensively, and progeny virions harvested 40 h later.
Alternatively, 293T cells were transfected with the indicated
amounts of the HIV-1(NL4-3) proviral plasmid and virions were
harvested 40 h later. Cell and virion lysates were analyzed by
Western blotting with anti-Gag and clathrin HC antibodies, and
fluorescent detection reagents for quantitation of signals (LI-
COR). Virions were concentrated 5-fold during harvest and this
was taken into account when calculating the percentage of the
total clathrin HC in the entire culture that was present in virions
rather than cells, which is indicated for lanes 2, 4 and 7.
(TIF)
Figure S2 Effects of IN mutations on clathrin incorporation into
HIV-1 virions. 293T cells were transfected with protease-active
and various protease-defective (D25A) HIV-1 proviral plasmids,
including those that were otherwise either wild-type, or bore point
mutations in IN (E152K, N184L, F185K). Cells and virions were
analyzed by Western blotting with anti-Gag and clathrin HC
antibodies.
(TIF)
Figure S3 Depletion and sequestration of clathrin using siRNAs
and AP180C. (A) Two examples of clathrin HC depletion using
siRNA. 293T cells were cotransfected with an HIV-1 proviral
plasmid and luciferase (siLuc) or clathrin HC (siClath. HC)
targeting siRNAs as described in materials and methods. Cell
lysates were probed with anti-clathrin HC and anti-tubulin
antibodies. Western blot signals were quantitated using a LiCOR
Odyssey scanner and the clathrin protein levels were reduced by
7864%. (B) Clathrin sequestration using AP180C. 293T cells
stably expressing DsRed-Clathrin LC (Red) cells were transfected
with plasmids expressing FLAG-tagged AP180N (left panels) or
AP180C (right panels) and subjected to immunofluorescent
staining with an anti-FLAG antibody (green). Images were
acquired using a deconvolution microscope and Optical sections
at the center of the vertical dimension of the cell and at the cell-
coverslip interface are displayed.
(TIF)
Figure S4 Effects of IN mutations on levels of Pol proteins (RT
and IN) in HIV-1 virions. 293T cells were transfected with
protease-active HIV-1 (NL4-3) proviral plasmids that were either
wild-type, or bore point mutations (E152K, N184L, F185K) or a
truncation (dCTD). Cells were analyzed by Western blotting with
anti-Gag antibody, while virion lysates were probed with anti-Gag,
anti-RT and anti-IN antibodies.
(TIF)
Figure S5 Effects of AP180C expression on incorporation of
clathrin into HIV-1 virions. 293T cells were transfected with
codon optimized HIV-1 GagPol expression plasmid and either an
empty vector or increasing amounts of an AP180C expression
plasmid. Cells and virion lysates were analyzed by Western
blotting with anti-Gag, and anti-clathrin-HC antibodies.
(TIF)
Figure S6 Effects of AP180C expression on the Env protein in
HIV-1 virions. 293T cells were transfected with HIV-1 (NL4-3)
proviral plasmids and either an empty vector or plasmids
expressing AP180-N or AP180-C, as indicated. Cells and virion
lysates were analyzed by Western blotting with anti-Gag and anti-
Env (gp120) antibodies.
(TIF)
Figure S7 Additional examples of scanning EM images of 293T
cells transfected with plasmids expressing codon optimized WT or
the indicated mutant SIVmac Gag-IRES eGFP cassettes.
(TIF)
Figure S8 Additional examples of scanning EM images of 293T
cells transfected with plasmids expressing codon optimized
SIVmac Gag-IRES eGFP cassettes in presence of AP180C.
(TIF)
Figure S9 DLL- mutations in MLV GagPol affect the viral
protease in cis but not in trans. Cells were transfected with a fixed
amount (50 ng) of plasmids expressing wild-type (left panels) or
DLL-mutant (right panels) MLV GagPol and increasing amounts
(0, 25, 50, 100, 200, 400, 800 ng) of wild-type or DLL-mutant
MLV Gag-only expression plasmid. Cell lysates and virions were
subjected to Western blot analysis and were probed with anti-p12
(upper 4 panels) and anti-capsid (lower 4 panels) monoclonal
antibodies.
(TIF)
Figure S10 The MA-p12 junction can be cleaved by an MLV
protease in trans. Cells were transfected with 6 mg of a plasmid
expressing wild-type XMRV GagPol and 300 ng of a plasmid
expressing wild-type or DLL-mutant MLV Gag. Cell lysates and
virions were subjected to Western blot analysis and were probed
with anti-p12 (upper panels) and anti-capsid (lower panels)
monoclonal antibodies.
(TIF)
Figure S11 (A) Transmission electron microscopic analysis of
cells transfected with a DLL-mutant MLV proviral plasmid,
revealing particles of grossly normal morphology. (B) Western blot
analysis of virions and VLPs used in the TRIM5 saturation assays
(Figure 8I) to verify that approximately equivalent quantities of
physical particles were used.
(TIF)
Table S1 Requirements for DsRed-clathrin LC incorporation
into HIV-1 VLPs. GFP+ VLPs were generated by co-transfection
of 293T/DsRed-clathrin-LC cells with Gag or GagPol expression
plasmids and Gag-GFP in a 4:1 ratio and filtered VLPs (0.22 mm)
were applied to a microscope slide. Alternatively, a proviral
plasmid encoding YFP embedded in the stalk region of MA was
used (HIV-1 MA-YFP). See materials and methods for details.
Three fields containing between 500 and 1500 GFP or YFP+
VLPs were evaluated for DsRed-clathrin LC incorporation using
NIH IMAGE.
(DOC)
Table S2 Summary of the effects of mutations that block
clathrin incorporation on retroviruses.
(DOC)
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